"Tetrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013777
|
| MeSH Number(s) |
D03.383.129.617
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrazoles".
Below are MeSH descriptors whose meaning is more specific than "Tetrazoles".
This graph shows the total number of publications written about "Tetrazoles" by people in this website by year, and whether "Tetrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 3 | 0 | 3 |
| 2017 | 30 | 10 | 40 |
| 2018 | 26 | 5 | 31 |
| 2019 | 9 | 4 | 13 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Tetrazoles" by people in Profiles.
-
Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease. Sci Rep. 2021 08 19; 11(1):16843.
-
National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017-2020. J Glob Antimicrob Resist. 2021 09; 26:308-316.
-
Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study. Int J Infect Dis. 2021 Jul; 108:159-166.
-
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? Clin Sci (Lond). 2021 04 30; 135(8):1009-1014.
-
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci (Lond). 2021 02 12; 135(3):465-481.
-
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19. Med Hypotheses. 2021 Feb; 147:110486.
-
The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19. Int J Mol Sci. 2020 Nov 15; 21(22).
-
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions]. G Ital Cardiol (Rome). 2020 Oct; 21(10):750-756.